Key result
Intravenous prostacyclins provide long-term clinical benefits and improved survival for advanced pulmonary arterial hypertension, requiring specialized nursing competency for administration.
This review provides a practical guide for nurses on the characteristics, dosing, side effects, and titration of intravenous prostacyclins for advanced pulmonary arterial hypertension.
Emphasizes need for specialized nursing competency with IV prostacyclins in advanced PAH; leaves open prospective trials to confirm survival benefits.
Pulmonary arterial hypertension (PAH) is a severely disabling disorder characterized by elevated pulmonary artery pressure ultimately leading to right heart failure and death. Treatment options have significantly increased over the past decade. Intravenous prostacyclins remain the treatment of choice for advanced PAH, leading to long-term clinical benefits and improved survival. Their administration requires a high level of nursing competency and presents considerable challenges for patients and caregivers. This article reviews the characteristics of currently available intravenous prostacyclins and provides a practical guide for nurses who may have had limited exposure to intravenous prostacyclins and their unique dosing, side effects, and titration characteristics.
No takes yet. Share an insight, caveat, or question.
Martha Kingman (2014) conducted a review in Pulmonary arterial hypertension. Intravenous prostacyclins was evaluated. Intravenous prostacyclins provide long-term clinical benefits and improved survival for advanced pulmonary arterial hypertension, requiring specialized nursing competency for administration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: